PTPN11

Structure

PTPN11 encodes the protein tyrosine phosphatase SHP2, which has a modular structure essential for its regulatory function in cell signaling. SHP2 consists of two tandem Src homology 2 (SH2) domains at the N-terminus (N-SH2 and C-SH2), followed by a catalytic protein tyrosine phosphatase (PTP) domain and a C-terminal tail containing tyrosyl phosphorylation sites. In its inactive, auto-inhibited conformation, the N-SH2 domain binds intramolecularly to the PTP catalytic domain, blocking substrate access to the active site. Upon binding to phosphotyrosyl residues on target proteins, the N-SH2 domain undergoes a conformational change that releases the PTP domain, thereby activating the enzyme. The catalytic domain itself adopts a conserved fold characteristic of classical PTPs, featuring a catalytic loop (WPD loop) that undergoes conformational changes during substrate binding and catalysis. This structural arrangement allows SHP2 to tightly regulate signaling pathways by selectively dephosphorylating substrates involved in cell growth, differentiation, and migration. Mutations disrupting the interface between the N-SH2 and PTP domains can lead to constitutive activation or impairment of SHP2, underlying diseases such as Noonan syndrome and certain leukemias. The overall structure has been elucidated by multiple crystallographic studies, revealing both the auto-inhibited and active states, which provide insight into its mechanism of regulation and function in diverse cellular contexts.

Function

PTPN11 encodes SHP2, a ubiquitously expressed protein tyrosine phosphatase that plays an important role in regulating cell signaling pathways, most notably the RAS/MAPK cascade, which controls cell proliferation, differentiation, migration, and survival. SHP2 acts as a positive regulator of signal transduction by dephosphorylating specific phosphotyrosine residues on target proteins, thereby facilitating the propagation of growth factor and cytokine signals. During embryonic development, SHP2 is essential for the formation of the heart, blood cells, bones, and other tissues. Germline mutations in PTPN11 cause developmental disorders such as Noonan syndrome and LEOPARD syndrome, while somatic mutations are frequently implicated in hematologic malignancies and solid tumors by promoting aberrant activation of oncogenic pathways. In cancer, SHP2 can function as an oncogenic driver by sustaining RAS/RAF/MAPK signaling and supporting tumor cell growth and survival. Thus, PTPN11/SHP2 is a critical regulator of both normal cellular processes and disease states, with its dysregulation contributing to developmental syndromes and oncogenesis.

Clinical significance

Missense mutations in the PTPN11 locus are associated with both Noonan syndrome and Leopard syndrome. At least 79 disease-causing mutations in this gene have been discovered.

Noonan syndrome

In the case of Noonan syndrome, mutations are broadly distributed throughout the coding region of the gene but all appear to result in hyper-activated, or unregulated mutant forms of the protein. Most of these mutations disrupt the binding interface between the N-SH2 domain and catalytic core necessary for the enzyme to maintain its auto-inhibited conformation.

Leopard syndrome

The mutations that cause Leopard syndrome are restricted regions affecting the catalytic core of the enzyme producing catalytically impaired Shp2 variants. It is currently unclear how mutations that give rise to mutant variants of Shp2 with biochemically opposite characteristics result in similar human genetic syndromes.

Metachondromatosis

It has also been associated with metachondromatosis.

Cancer

Patients with a subset of Noonan syndrome PTPN11 mutations also have a higher prevalence of juvenile myelomonocytic leukemias (JMML). Activating Shp2 mutations have also been detected in neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, lung cancer, colorectal cancer. Recently, a relatively high prevalence of PTPN11 mutations (24%) were detected by next-generation sequencing in a cohort of NPM1-mutated acute myeloid leukemia patients, although the prognostic significance of such associations has not been clarified. These data suggests that Shp2 may be a proto-oncogene. However, it has been reported that PTPN11/Shp2 can act as either tumor promoter or suppressor. In aged mouse model, hepatocyte-specific deletion of PTPN11/Shp2 promotes inflammatory signaling through the STAT3 pathway and hepatic inflammation/necrosis, resulting in regenerative hyperplasia and spontaneous development of tumors. Decreased PTPN11/Shp2 expression was detected in a subfraction of human hepatocellular carcinoma (HCC) specimens. The bacterium Helicobacter pylori has been associated with gastric cancer, and this is thought to be mediated in part by the interaction of its virulence factor CagA with SHP2.

H Pylori CagA virulence factor

CagA is a protein and virulence factor inserted by Helicobacter pylori into gastric epithelia. Once activated by SRC phosphorylation, CagA binds to SHP2, allosterically activating it. This leads to morphological changes, abnormal mitogenic signals and sustained activity can result in apoptosis of the host cell. Epidemiological studies have shown roles of cagA- positive H. pylori in the development of atrophic gastritis, peptic ulcer disease and gastric carcinoma.

Interactions

PTPN11 has been shown to interact with

• CagA,
• Cbl gene,
• CD117,
• CD31,
• CEACAM1,
• Epidermal growth factor receptor,
• Erk
• FRS2,
• GAB1,
• GAB2,
• GAB3,
• Glycoprotein 130,
• Grb2,
• Growth hormone receptor,
• HoxA10,
• Insulin receptor,
• Insulin-like growth factor 1 receptor,
• IRS1,
• Janus kinase 1,
• Janus kinase 2,
• LAIR1,
• LRP1,
• PDGFRB,
• PI3K → Akt
• PLCG2,
• PTK2B,
• Ras
• SLAMF1,
• SOCS3,
• SOS1,
• STAT3,
• STAT5A, and
• STAT5B.

Ligands

;Inhibitors

• Batoprotafib
• SHP099
• Sitneprotafib
• Vociprotafib (RMC-4630)

;AUTACs

• SA-8

References

References

1. (December 1994). "Mapping a gene for Noonan syndrome to the long arm of chromosome 12". Nature Genetics.
2. (December 1992). "Identification of a human Src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew". Proceedings of the National Academy of Sciences of the United States of America.
3. "Entrez Gene: PTPN11 protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1)".
4. (2025-05-28). "PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution". Frontiers in Immunology.
5. (2014-04-15). "Distinct and overlapping functions of ptpn11 genes in Zebrafish development". PLOS ONE.
6. (June 2003). "The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling". Trends in Biochemical Sciences.
7. (June 2003). "Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia". Nature Genetics.
8. (February 1998). "Inositol trisphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in C. elegans". Cell.
9. (December 2001). "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome". Nature Genetics.
10. (2016). "[The Biological Function of SHP2 in Human Disease]". Molekuliarnaia Biologiia.
11. (February 2006). "Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease". American Journal of Human Genetics.
12. (February 2019). "PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas". Molecular Cancer Research.
13. (December 2019). "Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases". Scientific Reports.
14. (June 2002). "PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity". American Journal of Human Genetics.
15. (January 2007). "Germline gain-of-function mutations in SOS1 cause Noonan syndrome". Nature Genetics.
16. (March 2006). "PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects". The Journal of Biological Chemistry.
17. (August 2002). "PTPN11 mutations in LEOPARD syndrome". Journal of Medical Genetics.
18. (June 2010). "Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene". PLOS Genetics.
19. (December 2004). "Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia". Cancer Research.
20. (May 2018). "High NPM1 mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML". Blood.
21. (May 2011). "Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis". Cancer Cell.
22. (Dec 2005). "Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis". Cancer Science.
23. (September 2004). "Oncogenic mechanisms of the Helicobacter pylori CagA protein". Nature Reviews. Cancer.
24. (Aug 2008). "c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130". Molecular and Cellular Biology.
25. (October 1994). "The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells". Journal of Biological Chemistry.
26. (April 1998). "SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain". Molecular and Cellular Biology.
27. (July 2000). "Platelet-endothelial cell adhesion molecule-1 (CD31), a scaffolding molecule for selected catenin family members whose binding is mediated by different tyrosine and serine/threonine phosphorylation". Journal of Biological Chemistry.
28. (April 1999). "Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31". FEBS Letters.
29. (October 1998). "Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates". Journal of Biological Chemistry.
30. (March 1997). "The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1- and integrin-mediated cellular signaling". Journal of Biological Chemistry.
31. (Jan 1999). "The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells". Journal of Biological Chemistry.
32. (2005). "Phosphotyrosine interactome of the ErbB-receptor kinase family". Molecular Systems Biology.
33. (Sep 1995). "Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C". Journal of Biological Chemistry.
34. (2004). "Protein phosphatases". Springer.
35. (June 2003). "The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling". Trends in Biochemical Sciences.
36. (Feb 2000). "Potential involvement of FRS2 in insulin signaling". Endocrinology.
37. (Apr 2001). "Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction". Oncogene.
38. (Jul 1998). "Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation". Molecular and Cellular Biology.
39. (Jun 2002). "Protein kinase C-alpha and protein kinase C-epsilon are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor". Journal of Biological Chemistry.
40. (Jul 1998). "Determination of Gab1 (Grb2-associated binder-1) interaction with insulin receptor-signaling molecules". Molecular Endocrinology.
41. (January 2002). "PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2". The EMBO Journal.
42. (July 1999). "Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1". Journal of Biological Chemistry.
43. (April 2001). "A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners". FEBS Letters.
44. (Jan 2002). "Gab3, a New DOS/Gab Family Member, Facilitates Macrophage Differentiation". Molecular and Cellular Biology.
45. (Sep 2000). "Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation". Journal of Immunology.
46. (Dec 1997). "Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells". Journal of Biological Chemistry.
47. (Jun 2000). "Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk". Journal of Biological Chemistry.
48. (Jul 1994). "Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras". Proceedings of the National Academy of Sciences of the United States of America.
49. (Nov 1998). "Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.
50. (Oct 1997). "Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor". Oncogene.
51. (Apr 1999). "Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells". Journal of Biological Chemistry.
52. (Mar 1999). "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells". Journal of Leukocyte Biology.
53. (Aug 1996). "Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2". Journal of Biological Chemistry.
54. (September 2000). "Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B". Molecular Endocrinology.
55. (June 1998). "Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins". Journal of Biological Chemistry.
56. (Jan 2009). "Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia.". Journal of Biological Chemistry.
57. (Mar 1994). "Insulin receptor kinase phosphorylates protein tyrosine phosphatase containing Src homology 2 regions and modulates its PTPase activity in vitro". Biochemical and Biophysical Research Communications.
58. (Dec 1995). "Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction". Journal of Biological Chemistry.
59. (Apr 1999). "Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility". Molecular and Cellular Biology.
60. (Aug 1995). "Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein". Journal of Biological Chemistry.
61. (Jun 1993). "The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp". Journal of Biological Chemistry.
62. (Oct 1998). "The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling". Journal of Biological Chemistry.
63. (January 2003). "SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130". Journal of Biological Chemistry.
64. (January 1997). "Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases". Journal of Biological Chemistry.
65. (June 1996). "Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis". Blood.
66. (November 1996). "SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates". Biochemical and Biophysical Research Communications.
67. (Aug 2000). "FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells". Journal of Immunology.
68. (Aug 1997). "LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes". Immunity.
69. (June 2008). "Structural and functional consequences of tyrosine phosphorylation in the LRP1 cytoplasmic domain". Journal of Biological Chemistry.
70. (Jan 2001). "Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1". The Journal of Cell Biology.
71. (Oct 1993). "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor". Journal of Biological Chemistry.
72. (October 2002). "Phosphatidylinositol 3-kinase regulates glycosylphosphatidylinositol hydrolysis through PLC-gamma(2) activation in erythropoietin-stimulated cells". Cellular Signalling.
73. (September 2000). "SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells". Journal of Biological Chemistry.
74. (Feb 2000). "Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation". Blood.
75. (Nov 2001). "Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells". The EMBO Journal.
76. (Oct 1997). "Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells". Biochemical and Biophysical Research Communications.
77. (Jan 2000). "Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation". Journal of Biological Chemistry.
78. (Aug 2002). "Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells". Journal of Biological Chemistry.
79. Guo W, Xu Q. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds. ''J Pharmacol Sci''. 2020 Nov;144(3):139-146. {{doi. 10.1016/j.jphs.2020.06.002 {{pmid. 32921395
80. Kang D, Wang Y, Lin Y, Ma WW, Morgensztern D, Leventakos K, Bi C, Ding Y, Xiong J, Yan M, Sun X, Wang P, Ma C, Wang Y. JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. ''Clin Cancer Res''. 2025 Jul 15;31(14):3019-3032. {{doi. 10.1158/1078-0432.CCR-24-3691 {{pmid. 40333694
81. Luo J, Villaruz LC. Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer. ''Lancet Respir Med''. 2025 Nov 28:S2213-2600(25)00298-X. {{doi. 10.1016/S2213-2600(25)00298-X {{pmid. 41325754
82. Song H, Zou X, Liang J, Huang H, Liu Y, Zhang Y, Liu Y, Chen L, Li H. Discovery of SA-8 as a potent SHP2-AUTAC degrader in cancer therapy. ''Eur J Med Chem''. 2025 Nov 5;297:117918. {{doi. 10.1016/j.ejmech.2025.117918 {{pmid. 40609222